Merck’s Keytruda Shows Mixed Results in Lung Cancer Study

Merck released results from the Phase III KEYNOTE-604 trial of its checkpoint inhibitor Keytruda (pembrolizumab) with chemotherapy in extensive-stage small cell lung cancer (ES-SCLC). The study met one of its dual primary endpoints, progression-free survival (PFS), but missed the other endpoint, overall survival (OS).